πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital β€” phase, modality, and trial IDs.

Programs
149

Quick answer

First People's Hospital has 149 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Ritonavir for cycle1 and NORVIR for cycle 2

    The First People's Hospital of Lianyungang

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  2. Rituximab

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma Recurrent

    phase 1 small molecule active

    1 trial

  3. SCT510

    The First People's Hospital of Lianyungang

    Healthy

    phase 1 small molecule completed

    1 trial

  4. SIG001

    The First People's Hospital of Lianyungang

    Neoplams

    phase 1 mab active

    1 trial

  5. SZ011 CAR-NK

    The First People's Hospital of Lianyungang

    Advanced Triple Negative Breast Cancer

    phase 1 small molecule active

    1 trial

  6. Salvianolic Acid A

    The First People's Hospital of Lianyungang

    Neuropathy of Diabetes

    phase 1 small molecule active

    1 trial

  7. Serine（OralοΌ‰

    The First People's Hospital of Lianyungang

    Advanced Colorectal Cancer

    phase 1 small molecule active

    1 trial

  8. Shenkang decoction

    The First People's Hospital of Lianyungang

    Chronic Renal Failure

    phase 1 small molecule completed

    1 trial

  9. Sonodynamic therapy (SDT)

    The First People's Hospital of Lianyungang

    Carotid Atherosclerosis

    phase 1 other completed

    1 trial

  10. T cell injection targeting CD7 chimeric antigen receptor

    The First People's Hospital of Lianyungang

    T Lymphoblastic Leukemia/Lymphoma

    phase 1 mab active

    1 trial

  11. T cell injection targeting CD7 chimeric antigen receptor

    The First People's Hospital of Lianyungang

    CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

    phase 1 mab active

    1 trial

  12. TALEN

    The First People's Hospital of Lianyungang

    Human Papillomavirus-Related Malignant Neoplasm

    phase 1 mab active

    1 trial

  13. TCR-T cells

    The First People's Hospital of Lianyungang

    Recurrent Hepatocellular Carcinoma

    phase 1 mab active

    1 trial

  14. TNP-2092 capsules

    The First People's Hospital of Lianyungang

    Helicobacter Pylori Infection

    phase 1 small molecule completed

    1 trial

  15. ThisCART19A

    The First People's Hospital of Lianyungang

    Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  16. ThisCART19A with Dose Level 1

    The First People's Hospital of Lianyungang

    CAR

    phase 1 small molecule active

    1 trial

  17. ThisCART22 cells injection

    The First People's Hospital of Lianyungang

    B Cell Malignancy

    phase 1 mab active

    1 trial

  18. Tranilast

    The First People's Hospital of Lianyungang

    Mucinoses

    phase 1 small molecule active

    1 trial

  19. Triprorelin for injection

    The First People's Hospital of Lianyungang

    Prostate Cancer (CRPC)

    phase 1 small molecule active

    1 trial

  20. U96

    The First People's Hospital of Lianyungang

    Relapsed or Refractory B Cell Leukemia and Lymphoma

    phase 1 small molecule active

    1 trial

  21. UB-VV410

    The First People's Hospital of Lianyungang

    Systemic Lupus Erythematosus

    phase 1 small molecule active

    1 trial

  22. UTAA09 injection

    The First People's Hospital of Lianyungang

    Recurrent or Refractory B-cell Non Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  23. Visual Sputum Suctioning System

    The First People's Hospital of Lianyungang

    Ineffective Airway Clearance

    phase 1 other active

    1 trial

  24. Voriconazole 200mg

    The First People's Hospital of Lianyungang

    Cryptococcal Meningitis

    phase 1 small molecule active

    1 trial

  25. [14C]HSK7653

    The First People's Hospital of Lianyungang

    Type II Diabetes

    phase 1 small molecule completed

    1 trial

  26. [14C]TGRX-326

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  27. [177Lu]Lu-XT117

    The First People's Hospital of Lianyungang

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  28. [18F]APN-1607

    The First People's Hospital of Lianyungang

    Alzheimer Disease

    phase 1 small molecule active

    1 trial

  29. [68Ga]Ga-Sa-DABI-4

    The First People's Hospital of Lianyungang

    Stimulator of Interferon Gene

    phase 1 small molecule active

    1 trial

  30. aerosol inhaled amikacin

    The First People's Hospital of Lianyungang

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 1 small molecule completed

    1 trial

  31. anti CD19 CAR NK cells

    The First People's Hospital of Lianyungang

    Antisynthetase Syndrome

    phase 1 mab active

    1 trial

  32. anti-CD19 CAR-T

    The First People's Hospital of Lianyungang

    B-cell Adult Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  33. anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells

    The First People's Hospital of Lianyungang

    Relapsed/refractory Lymphoma

    phase 1 mab active

    1 trial

  34. blinatumomab and auto-HSCT "sandwich " strategy

    The First People's Hospital of Lianyungang

    B-cell Acute Lymphoblastic Leukemia

    phase 1 other active

    1 trial

  35. bronchial basal cells

    The First People's Hospital of Lianyungang

    Chronic Respiratory Disease

    phase 1 mab active

    1 trial

  36. cisplatin oxaliplatin tegafur

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 1 small molecule active

    1 trial

  37. dexlansoprazole injection

    The First People's Hospital of Lianyungang

    Safety Issues

    phase 1 small molecule completed

    1 trial

  38. domestic polysaccharide superparamagnetic iron oxide nanoparticle

    The First People's Hospital of Lianyungang

    Chronic Kidney Diseases

    phase 1 small molecule completed

    1 trial

  39. fRPE cells

    The First People's Hospital of Lianyungang

    Age Related Macular Degeneration

    phase 1 small molecule active

    1 trial

  40. hCD19.IL15.CAR-iNKT

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  41. human HER2-targeted CAR-M cells

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 1 mab active

    1 trial

  42. narfurine hydrochloride orally disintegrating tablets

    The First People's Hospital of Lianyungang

    Improvement of Pruritus in Hemodialysis Patients

    phase 1 small molecule active

    1 trial

  43. pd-1 and DC-NK cells

    The First People's Hospital of Lianyungang

    Solid Tumor

    phase 1 small molecule active

    1 trial

  44. pd-1 and dc-cik cells

    The First People's Hospital of Lianyungang

    Solid Tumor

    phase 1 small molecule active

    1 trial

  45. prophylactic 4SCAR19 cells

    The First People's Hospital of Lianyungang

    B Acute Lymphoblastic Leukemia

    phase 1 gene therapy active

    1 trial

  46. salvianolic acid A

    The First People's Hospital of Lianyungang

    Diabetes

    phase 1 small molecule active

    1 trial

  47. salvianolic acid A

    The First People's Hospital of Lianyungang

    Healthy

    phase 1 small molecule active

    1 trial

  48. standard chemotherapy medicine combined with Chinese herbs

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

149 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.